HIV/AIDS-related visceral leishmaniasis: A clinical and epidemiological description of visceral leishmaniasis in northern Brazil

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 47, Issue 1, 2014, Pages 38-46

  de Albuquerque, Leonardo Cordenonzi Pedroso ^a   Mendonça, Iatan Rezende ^a   Cardoso, Polyana Nascimento ^a   Baldaçara, Leonardo Rodrigo ^a   Borges, Myrlena Regina Machado Mescouto ^a   Borges, Joelma da Costa ^a   Pranchevicius, Maria Cristina da Silva ^a  

^a UNIVERSIDADE FEDERAL DO TOCANTINS   (Brazil)

Author keywords

Epidemiology; HIV related visceral leishmaniasis; Public health; Urbanization; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BRAZIL; CHILD; CLINICAL FEATURE; CONCURRENT INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE TEST; INCIDENCE; INFANT; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; NEWBORN; PNEUMONIA; RECURRENCE RISK; SEPSIS; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; WESTERN BLOTTING;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BRAZIL; CHILD; CHILD, PRESCHOOL; EDUCATIONAL STATUS; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; RECURRENCE; YOUNG ADULT;

EID: 84895768069     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0180-2013     Document Type: Article

References (41)

1. Maia-Elkhoury ANS, Alves WA, Sousa-Gomes ML, Sena JM, Luna EA. Visceral leishmaniasis in Brazil: Trends and Challenges. Cad Saude Publica 2008; 24:2941-2947.
2. Alvar J, Aparicio P, Aseffa A, DenBoer M, Cañavate C, Dedet JP, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Micro Biol Rev 2008; 21:334-359.
3. Harhay MO, Olliaro PL, Costa DC, Costa CHN. Urban parasitology: visceral leishmaniasis in Brazil. Trends Parasitol 2011; 27:403-409.
4. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas and Bennett's principles and practice of infectious diseases, 6th Ed. Philadelphia (PA): Elsevier Churchill Livingstone; 2005 p. 2428-2442.
5. Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: dose and response. J Glob Infect Dis 2010; 2:159-166.
6. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde, Departamento de DST, AIDS e hepatites virais. Boletim Epidemiológico-AIDS e DST. Brasília: MS; 2012.
7. Cota GF, Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV infected patients: a systematic review. PLoS One 2011; e1153.
8. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, Cuevas LE, et al. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV coinfection in northwest Ethiopia. Trop Med Int Health 2010; 15:848-855.
9. Souza GF, Biscione F, Greco DB, Rabello A. Slow clinical improvement after treatment initiation in leishmania/HIV coinfected patients. Rev Soc Bras Med Trop 2012; 45:147-150.
10. Orsini M, Canela JR, Disch J, Maciel F, Greco D, Toledo Jr A, et al. High frequency of asymptomatic Leishmania spp. infection among HIVinfected patients living in endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg 2012; 106:283-288.
11. Sousa-Gomes ML, Maia-Elkhoury ANS, Pelissari DM, Lima Jr FEF, Sena JM, Cechinel MP. Coinfecção Leishmania-HIV no Brasil: aspectos epidemiológicos, clínicos e laboratoriais. Epidemiol Serv Saude 2011; 20:519-526.
12. Nascimento ET, Moura MLN, Queiroz JW, Barroso AW, Araujo AF, Rego EF, et al. The Emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil. Trans R Soc Trop Med Hyg 2011; 105:298-300.
13. Alexandrino-de-Oliveira P, Santos-Oliveira JR, Dorval MEC, Costa FCB, Pereira GROL, Cunha RV, et al. HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-West Brazil. Mem Inst Oswaldo Cruz 2010; 105:692-697.
14. World Health Organization (WHO). The Leishmaniasis and leishmania/ HIV Coinfection. WHO: 2000; [Cited 2013 September 03] Available at: apps. who. int/inf-fs/en/fact116. html/.
15. Daher EF, Fonseca PP, Gerhard ES, Leitão TM, Silva Júnior GB. Clinical and epidemiological features of visceral leishmaniasis and HIV Coinfection in fifteen patients from Brazil. J Parasitol 2009; 95:652-655.
16. Goés MAO, Melo CM, Jeraldo VLS. Série Temporal da leishmaniose visceral em Aracaju, Estado de Sergipe, Brasil (1999 a 2008): aspectos humanos e caninos. Rev Bras Epidemiol 2012; 15:298-307.
17. Botelho ACA, Natal D. Primeira descrição epidemiológica da leishmaniose visceral em Campo Grande, Estado do Mato Grosso do Sul. Rev Soc Bras Med Trop 2009; 42:503-508.
18. Sarkari B, Hatam G, Ghatee MA. Epidemiological features of visceral leishmaniasis in Fars Province, Southern Iran. Iranian J Publ Health 2012; 41:94-99.
19. Deribe K, Meribo K, Gebre T, Hailu A, Ali A, AseffaA, et al. The Burden of Neglected Tropical Diseases in Ethiopia, and opportunities for integrated control and elimination. Parasit Vectors 2012; 5:240.
20. Piscopo TV, Azzopardi CM. Leishmaniasis. Postgrad Med J 2007; 82: 649-657.
21. Mescouto-Borges MRM, Maués E, Costa DL, Pranchevicius MC, Romero GS. Congenitally transmitted visceral leishmaniasis: report of two Brazilian human cases. Braz J Infect Dis 2013; 17:263-266.
22. Maia-Elkhoury ANS, Lucena F, Sousa-Gomes ML, Alves WA, Paz L. Coinfecção da leishmaniose visceral e AIDS no Brasil. Rev Soc Bras Med Trop 2007; 40 (suppl I):124.
23. Fernandez Guerrero ML, Aguado JM, Buzon L, Barros C, Montalban C, Martin T, et al. Visceral leishmaniasis in immunocompromised Hosts. Am J Med 1987; 83:1098-1102.
24. Badaro R, Carvalho EM, Rocha H, Queiroz AC, Jones TC. Leishmania donovani: An opportunistic microbe associated with progressive disease in three immunocompromised patients. Lancet 1986; 1:647-648.
25. Jarvis JN, Lockwood DN. Clinical Aspects of Visceral Leishmaniasis in HIV infection. Curr Opin Infect Dis 2013; 26:1-9.
26. La Rosa R, Pineda JA, Delgado J, Macías J, Morillas F, Mira JA, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Micro Biol 2002; 40:762-767.
27. Berhe N, Wolday D, Hailu A, Abraham Y, Ali A, Gebre-Michael T, et al. HIV viral load and response to antileishmanial chemotherapy in coinfected patients. AIDS 1999; 13:1921-1925.
28. Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, et al. Leishmania and human immunodeficiency virus coinfection: The first 10 years. Clin Micro Biol Rev 1997; 10:298-319.
29. Grabmeier-Pfistershammer K, Poeppl W, Brunner PM, Rappersberger K, Rieger A. Clinical challenges in the management of Leishmania/HIV coinfection in a non-endemic area: a case report. Case Rep Infect Dis 2012; 2012:787305.
30. World Health Organization (WHO). Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. [Cited 2013 September 09] Available at: whqlibdoc. who. int/trs/WHO_TRS_949_eng. pdf. 2010/.
31. World Health Organization (WHO). Report of a WHO informal consultation on liposomal amphotericin B in the treatment of visceral leishmaniasis. WHO: 2005. [Cited 2013 September 09] Available at: http://www.who.int/ neglected_diseases/resources/AmBisomeReport.pdf. 2005
32. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica. Manual de recomendações para diagnóstico, tratamento e acompanhamento de pacientes com a coinfecção Leishmania-HIV. Brasília: MS; 2011.
33. Russo R, Laguna F, Lopez-Velez R, Medrano FJ, Rosenthal E, Cacopardo B, et al. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. An Trop Med Parasitol 2003; 97 (Suppl I):99-105.
34. Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702-1709.
35. Bentwich Z. Concurrent Infections that rise the HIV viral load. J HIV Ther 2003; 8:72-75.
36. Cacopardo B, Nigro L, Preiser, Famá A, Satariano MI, Braner J, et al. Prolonged Th2 cell activation and increased viral replication in HIVLeishmania coinfected patients despite treatment. Transactions Trans R Soc Trop Med Hyg 1996; 90:434-435.
37. Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, Bastien P. Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr 2008; 48:13-19.
38. Collin SM, Coleman PG, Ritmeijer K, Davidson RN. Unseen Kalaazar deaths in south Sudan (1999-2002). Trop Med Int Health 2006; 11: 509-512.
39. Oliveira JM, Fernandes AC, Dorval ME, Alves TP, Fernandes TD, Oshiro ET, et al. Mortality due to visceral leishmaniasis: Clinical and laboratory characteristics. Rev Soc Bras Med Trop 2010; 43:188-193.
40. Costa CH, Werneck GL, Costa DL, Holanda TA, Aguiar GB, Carvalho AS, et al. Is severe visceral leishmaniasis a systemic inflammatory response syndrome? a case control study. Rev Soc Bras Med Trop 2010; 43:386-392.
41. Sampaio MJAQ, Cavalcanti NV, Alves JGB, Fernandes Filho MJC, Correia JB. Risk factors for death in children with visceral leishmaniasis. PLoS Negl Trop Dis 2010; 4:e877.